Jo Bønding Andreasen

Jo Bønding Andreasen

Auto-generated profile, based on publicly available information

Jo Bønding Andreasen

Department of Anesthesiology and Intensive Care Aalborg University Hospital Aalborg Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
CACarl Thomas Anthon
Carl Thomas Anthon
FPFrédéric Pène
Frédéric Pène
APAnders Perner
Anders Perner
EAElie Azoulay
Elie Azoulay
KPKathryn Puxty
Kathryn Puxty
LRLene Russell
Lene Russell
Purpose Thrombocytopenia (platelet count < 150 × 109/L) is common in intensive care unit (ICU) patients and is likely associated with worse outcomes. In this study we present international contemporary data on thrombocytopenia in ICU patients. Methods We conducted a prospective cohort study in adult ICU patients in 52 ICUs across 10 countries. We assessed frequencies of thrombocytopenia, use of platelet transfusions and clinical outcomes including mortality. We evaluated pre-selected potential risk factors for the development of thrombocytopenia during ICU stay and associations between thrombocytopenia at ICU admission and 90-day mortality using pre-specified logistic regression analyses. Results We analysed 1166 ICU patients; the median age was 63 years and 39.5% were female. Overall, 43.2% (95% confidence interval (CI) 40.4–46.1) had thrombocytopenia; 23.4% (20–26) had thrombocytopenia at ICU admission, and 19.8% (17.6–22.2) developed thrombocytopenia during their ICU stay. Absence of acquired immune deficiency syndrome (AIDS), non-cancer-related immune deficiency, liver failure, male sex, septic shock, and bleeding at ICU admission were associated with the development of thrombocytopenia during ICU stay. Among patients with thrombocytopenia, 22.6% received platelet transfusion(s), and 64.3% of in-ICU transfusions were prophylactic. Patients with thrombocytopenia had higher occurrences of bleeding and death, fewer days alive without the use of life-support, and fewer days alive and out of hospital. Thrombocytopenia at ICU admission was associated with 90-day mortality (adjusted odds ratio 1.7; 95% CI 1.19–2.42). Conclusion Thrombocytopenia occurred in 43% of critically ill patients and was associated with worse outcomes including increased mortality. Platelet transfusions were given to 23% of patients with thrombocytopenia and most were prophylactic.

2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
EGEmilie Gregers
Emilie Gregers
KKKristian Kragholm
Kristian Kragholm
LLLouise Linde
Louise Linde
SMSivagowry Rasalingam Mørk
Sivagowry Rasalingam Mørk
JAJo Bønding Andreasen
Jo Bønding Andreasen
HSHelle Søholm
Helle Søholm
Background: Extracorporeal cardiopulmonary resuscitation (ECPR) is increasingly used for refractory out‐of‐hospital cardiac arrest (OHCA). However, survivors managed with ECPR are at risk of poor functional status. The purpose of this study was to investigate return to work (RTW) after refractory OHCA. Methods and Results: Of 44 360 patients with OHCA in the period of 2011 to 2020, this nationwide registry‐based study included 805 patients with refractory OHCA in the working age (18–65 years) who were employed before OHCA (2% of the total OHCA cohort). Demographics, prehospital characteristics, status at hospital arrival, employment status, and survival were retrieved through the Danish national registries. Sustainable RTW was defined as RTW for ≥6 months without any long sick leave relapses. Median follow‐up time was 4.1 years. ECPR and standard advanced cardiovascular life support were applied in 136 and 669 patients, respectively. RTW 1 year after OHCA was similar (39% versus 54%; P =0.2) and sustainable RTW was high in both survivors managed with ECPR and survivors managed with standard advanced cardiovascular life support (83% versus 85%; P >0.9). Younger age and shorter length of hospitalization were associated with RTW in multivariable Cox analysis, whereas ECPR was not. Conclusions: In refractory OHCA‐patients employed prior to OHCA, approximately 1 out of 2 patients were employed after 1 year with no difference between patients treated with ECPR or standard advanced cardiovascular life support. Younger age and shorter length of hospitalization were associated with RTW while ECPR was not.

5 June 2024 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
CACarl Thomas Anthon
Carl Thomas Anthon
FPFrédéric Pène
Frédéric Pène
APAnders Perner
Anders Perner
EAElie Azoulay
Elie Azoulay
KPKathryn Puxty
Kathryn Puxty
LRLene Russell
Lene Russell
Background: Platelet transfusions are frequently used in the intensive care unit (ICU), but current practices including used product types, volumes, doses and effects are unknown. Study design and methods: Sub-study of the inception cohort study 'Thrombocytopenia and Platelet Transfusions in the ICU (PLOT-ICU)', including acutely admitted, adult ICU patients with thrombocytopenia (platelet count <150 x 10(9)/L). The primary outcome was the number of patients receiving platelet transfusion in ICU by product type. Secondary outcomes included platelet transfusion details, platelet increments, bleeding, other transfusions and mortality. Results: Amongst 504 patients with thrombocytopenia from 43 hospitals in 10 countries in Europe and the United States, 20.8% received 565 platelet transfusions; 61.0% received pooled products, 21.9% received apheresis products and 17.1% received both with a median of 2 (interquartile range 1-4) days from admission to first transfusion. The median volume per transfusion was 253 mL (180-308 mL) and pooled products accounted for 59.1% of transfusions, however, this varied across countries. Most centres (73.8%) used fixed dosing (medians ranging from 2.0 to 3.5 x 10(11) platelets/transfusion) whilst some (mainly in France) used weight-based dosing (ranging from 0.5 to 0.7 x 10(11) platelets per 10 kg body weight). The median platelet count increment for a single prophylactic platelet transfusion was 2 (-1 to 8) x 10(9)/L. Outcomes of patients with thrombocytopenia who did and did not receive platelet transfusions varied. Conclusions: Among acutely admitted, adult ICU patients with thrombocytopenia, 20.8% received platelet transfusions in ICU of whom most received pooled products, but considerable variation was observed in product type, volumes and doses across countries. Prophylactic platelet transfusions were associated with limited increases in platelet counts.

16 August 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
KAKirstine Krushave Akkaoui
Kirstine Krushave Akkaoui
LALjubica Vukelic Andersen
Ljubica Vukelic Andersen
MNMartin Agge Nørgaard
Martin Agge Nørgaard
JAJo Bønding Andreasen
Jo Bønding Andreasen
Metformin-associated lactic acidosis (MALA) is a serious condition with high mortality. This case describes a man in the mid-60s with diabetes mellitus type 2 treated with metformin developing MALA 4 days after coronary stenting for non-ST-elevation myocardial infarction. He presented acutely with severe abdominal pain, a lactate of 19 mmol/L and pH 6.74. Despite treatment for MALA, he went into refractory cardiac arrest and was connected to venoarterial extracorporeal membrane oxygenation (VA-ECMO). He suffered a massive haemothorax due to perforation of the right atrial appendage. It was repaired through a sternotomy while being given massive blood transfusions. The following days, he was on VA-ECMO and double continuous venovenous haemodialysis (CVVHD). He survived with only mild paresis of the left hand. VA-ECMO should be considered a rescue therapy alongside treatment with CVVHD in case of cardiac arrest due to severe MALA.

7 March 2024 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
BEBirgitta Ehrnström
Birgitta Ehrnström
MHMaria Schei Haugan
Maria Schei Haugan
JAJo Bønding Andreasen
Jo Bønding Andreasen
AEAsbjørn Ellingsen
Asbjørn Ellingsen
Infection in the immunocompromised patient is often challenging on multiple levels. It can be difficult to distinguish between manifestations of the underlying disease, infection or malignancy. Symptoms may be vague or even absent, deviations in the common inflammatory parameters discrete, imaging findings scarce and the causative microbe may be a true pathogen as well as opportunistic. Here, we report an immunosuppressed female in her late teens with a purulent meningitis due to Ureaplasma parvum—a very rare cause of infection in the central nervous system of adults. We wish to highlight the relevance of intracellular pathogens and the need to actively search for these microbes, especially when response to broad-spectrum antibiotic treatment is absent. Furthermore, we emphasise the need for adequate molecular microbial diagnostics in search of microbes that are difficult to identify by culture and where serology and antigen tests may be absent or unreliable due to immune suppression.

7 June 2026 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
AGAnders Morten Grejs
Anders Morten Grejs
JKJesper Kjaergaard
Jesper Kjaergaard
JAJo Bønding Andreasen
Jo Bønding Andreasen
BRBodil Steen Rasmussen
Bodil Steen Rasmussen
CHChristian Hassager
Christian Hassager
JMJacob Eifer Møller
Jacob Eifer Møller
Background: Survivors of out‐of‐hospital cardiac arrest (OHCA) who remain comatose after return of spontaneous circulation are routinely sedated and mechanically ventilated during early post‐resuscitation care. Although prolonged sedation has traditionally been considered necessary, contemporary normothermia‐based temperature control allows earlier wake‐up call. The optimal timing of an early wake‐up call remains unknown and may influence overall mortality, neurological recovery, duration of mechanical ventilation, and length of hospital stay. Methods: The Danish Out‐of‐Hospital Cardiac Arrest (DANOHCA) trial (clinicaltrials.gov identifier: NCT05895838; and euclinicaltrials.eu, identifier: 2024–515,997–28‐00) is an investigator‐initiated, multicenter, randomized clinical trial using a 2 × 2 × 2 × 2 factorial design evaluating four interventions in patients resuscitated from OHCA. The present protocol describes the comparison of an early versus late wake‐up call strategy. Adult patients (≥ 18 years) with presumed cardiac‐cause of OHCA, sustained return of spontaneous circulation, and persistent unconsciousness on intensive care unit admission are randomized 1:1 to early wake‐up call (≤ 6 h after randomization) or late wake‐up call (28–36 h after randomization). Wake‐up call includes interruption of sedation, assessment of neurology, and may be followed by extubation if predefined neurological and respiratory criteria are fulfilled. The primary endpoint is days alive and out of hospital within 30 days after randomization. Analyses will follow a modified intention‐to‐treat principle. Perspectives: Optimizing post‐resuscitation care remains a cornerstone in managing comatose cardiac arrest survivors and improving outcomes. We hypothesize that sedation for 28–36 h leads to more days alive outside of the hospital in 30 days compared to sedation for ≤ 6 h. Trial Registration: EudraCT number: 2016‐003265‐26; EU CTIS no 2024‐515997‐28‐00; ClinicalTrials.gov identifier: NCT05895838.